A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee

Boehringer Ingelheim

Status and phase: Completed; Phase 4

Conditions: Osteoarthritis

Treatments: Drug: Meloxicam

Study type: Interventional

Funder types: Industry

Identifiers

NCT02183116

107.228

Details and patient eligibility

About

To Access the Efficacy and Safety of Meloxicam 7.5mg once daily over a treatment period of 56 days

Enrollment: 30 patients

Sex: All

Ages: 34 to 74 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Osteoarthritis of the knee requiring the therapy with non-steroidal anti-inflammatory drugs (NSAIDs)

Exclusion criteria

none

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Meloxicam

Experimental group

Treatment:

Drug: Meloxicam